Apple isn't the biggest winner from Trump's plans for a tax holiday. These three stocks are...
The French drugs maker lead gainers in the Paris market after profits beat analyst consensus by about 13%.
Sales of cancer drug Opdivo were up 60% year-over-year, while sales of blood thinner Eliquis grew 50%.
Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.
The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.
Akebia after the market close on Tuesday announced an expanded partnership with Japan's Otsuka Pharmaceuticals to develop and market its anemia pill Vadadustat in Europe, China and other territories.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.